Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer


Jilin University




Lung Cancer


Drug: Sintilimab plus chemotherapy

Study type


Funder types




Details and patient eligibility


Predicting relapse and overall survival in potentially resectable Stage IIIA-IIIB Non-small Cell Lung Cancer (NSCLC) patients remains challenging. It is now widely recognized that patients with detectable MRD have a worse prognosis than those with undetectable MRD. Therefore, investigators performed this prospective clinical trial to evaluate the predictive value of MRD with increased risk of relapse and improves prediction of outcome in potentially resectable Stage IIIA-IIIB NSCLC with neoadjuvant chemoimmunotherapy. In this study, investigators will pay more attention to the long-term follow-up time and dynamic monitoring of MRD. The predictive value of MRD with Disease-free survival (DFS) rate was observed as the primary endpoint. Besides that, the correlation of MRD with major pathologic response (MPR) rate, pathologic complete response (pCR) rate,event-free survival(EFS) rate and overall survival (OS) were observed as the second endpoints. Investigators hope it will provide a new insight for these potentially resectable Stage IIA-IIIB NSCLC with neoadjuvant chemoimmunotherapy.


20 estimated patients




18 to 75 years old


No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 2.
  • Have previously untreated and histological examination confirms resectable stage II-IIIA/IIIB non-small cell lung cancer (according to the 8th edition of the AJCC TNM staging criteria), and the pathological type of squamous cell carcinoma and non-squamous cell carcinoma needs to be distinguished, and EGFR, ALK, and ROS1 should be negative for non-squamous non-small cell lung cancer
  • Adequate organ function and expected survival time ≥ 12 weeks;
  • Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients.

Key Exclusion Criteria:

  • Presence of mixed carcinoma component on histology.
  • Patients with other active malignancies within 5 years prior to enrollment.
  • Known active autoimmune diseases.
  • Currently participate in an interventional clinical study treatment or have been treated with another drug or investigational device within 4 weeks prior to the first dose.
  • Use of immunosuppressive agents within 14 days prior to the first dose of study treatment.
  • Presence of other uncontrolled serious medical conditions.

Trial design

20 participants in 1 patient group

immunotherapy and chemotherapy
Participants received two to three cycles of neoadjuvant chemoimmunotherapy before surgery. Adjuvant chemotherapy was also administered for 2-3 cycles after surgery. In addition, MRD was detected within 30 days before surgery, 1 week after surgery, 1 month ±7days after surgery, 6 months after surgery.
Drug: Sintilimab plus chemotherapy

Trial contacts and locations



Central trial contact

Kewei Ma

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems